Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 124 full-time employees. The company went IPO on 2020-12-04. The company is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. The company has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Dr. Omid Farokhzad est le Chairman of the Board de Seer Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action SEER ?
Le prix actuel de SEER est de $1.93, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Seer Inc ?
Seer Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Seer Inc ?
La capitalisation boursière actuelle de Seer Inc est de $108.8M
Est-ce que Seer Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Seer Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte